Latest European Markets News

Adslot Ltd reports a robust Q2 FY25 with significant contract wins for its StoreFront platform and a 43% quarter-on-quarter increase in monetised transaction value, despite ongoing challenges in the Australian market.

Little Green Pharma reports a robust 75% revenue increase to $9.5 million for December quarter, driven by strong European market growth and strategic product launches.

Medical Developments International has posted a robust improvement in operating cash flow and revenue for Q2 FY25, driven by higher demand and pricing for its flagship product Penthrox across Australia and Europe.

Evion Group has initiated shipments from its expandable graphite joint venture in India, securing initial sales of A$2 million, while making significant progress on mining licenses and community support for its Maniry Graphite Project in Madagascar.

Unith Ltd has reported its strongest quarterly revenue in two years, driven by its B2C subscription division and strategic partnerships, while advancing its Digital Human technology and expanding into new markets.

AML3D Limited has reported a strong December quarter marked by significant defense contract completions, a $30 million capital raise, and strategic expansion into the US and European markets. The company is poised for accelerated growth, underpinned by a major US Navy funding boost and new sector entries.

Tesoro Gold reports its highest-ever gold assay at the Ternera Deposit alongside a strategic dual listing on the Frankfurt Stock Exchange and a strong cash position.

SciDev Ltd reports a seasonal revenue dip in Q2 FY25 due to US Oil & Gas sector uncertainty but marks a strategic milestone by securing its first PFAS treatment contracts in Europe.

Redivium's Q2 FY25 report reveals strategic progress in lithium-ion battery recycling across Europe, including new partnerships and feasibility studies, while navigating tight cash reserves and a critical entitlement offer.

Opyl Limited's Q2 FY25 update reveals robust progress through key partnerships, a new AI Biotech Fund launch, and strengthened financial footing, positioning the company for expanded influence in clinical trial optimisation.

OncoSil Medical has achieved a key regulatory milestone with MDR certification from BSI, removing post-market restrictions and streamlining its commercial operations across Europe. This approval also paves the way for renewed efforts to enter the Australian market.

Phoslock Environmental Technologies reported a widening cashflow deficit and disappointing sales in the December 2024 quarter, while legal challenges and share suspension continue to cloud its outlook.